Skip to content

Pfizer Inc

PFE· NYSExbrl foundCIK 78003

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -2.11%
Market cap
$164.33B
5.7B shares
Filings
1,085
$16.58B
Q3 2026−1.6% FY25 yoy
$3.24B
Q3 2026−3.2% FY25 yoy
—
—
—
$7.28B
Q3 2026derived−7.7% FY25 yoy
$0.56
Q3 2026−3.5% FY25 yoy
$1.82B
Q3 2026+9.5% FY25 yoy
$164.33B
40.7×
2.6×
1.8×
7.17%
—

Twelve months to Sep 27, 2026 · derived

Price

$28.83+13.01%+$3.32past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$62.58BFY 2025
$91.79B0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$62,579,000,000reported
FY 20242024-12-31$63,627,000,000reported
FY 20232023-12-31$50,914,000,000 revisedreported
FY 20222022-12-31$91,793,000,000 revisedreported
FY 20212021-12-31$73,636,000,000 revisedreported
FY 20202020-12-31$41,651,000,000 revisedreported
FY 20192019-12-31$40,905,000,000 revisedreported
FY 20182018-12-31$40,825,000,000 revisedreported
FY 20172017-12-31$52,546,000,000reported
FY 20162016-12-31$52,824,000,000reported
FY 20152015-12-31$48,851,000,000reported
FY 20142014-12-31$49,605,000,000reported

Capital returns

Dividends and buybacks · FY2015 to FY2024
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2024—$0.00$0.00$1.695.67B sh+0.4%0.0%
FY2023—$0.00$0.00$1.655.65B sh+0.5%0.0%
FY2022—$2.00B$2.00B$1.615.62B sh−0.1%7.7%
FY2021—$0.00$0.00$1.575.62B sh+0.8%0.0%
FY2020—$0.00$0.00$1.535.58B sh+0.5%0.0%

Segments

Revenue by Segments, FY2020 to FY2025FY2020Biopharma · FY2020 · $40.72BPC1 · FY2020 · $926.00MFY2021Biopharma · FY2021 · $79.56BBusiness Innovation Segment · FY2021 · $1.73BPC1 · FY2021 · $1.73BFY2022Biopharma · FY2022 · $99.83BBusiness Innovation Segment · FY2022 · $1.34BPC1 · FY2022 · $1.34BFY2023Biopharma · FY2023 · $58.24BBusiness Innovation Segment · FY2023 · $1.31BFY2024Biopharma · FY2024 · $62.40BFY2025Biopharma · FY2025 · $61.20B
LineFY2025ShareChange
Biopharma$61.20B98%−1.9%
Business Innovation Segment———
PC1———
Total$62.58B

From the 10-K filed Feb 26, 2026PFE

Pharmaceutical preparations

Pfizer Inc is the 4th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR